stock listing | GenomeWeb

stock listing

In December, the company effected a 1-for-10 reverse stock split in order to help regain compliance with Nasdaq's minimum closing bid requirement.

The firm recently enacted a 1-for-5 reverse stock split to help its shares meet the minimum bid price requirement for listing on the market.

As of Nov. 21 the company evidenced a closing bid price of its common stock in excess of the $1 minimum requirement for at least 10 consecutive trading days.

The molecular testing firm, which received a notice of potential delisting in January, said it may regain compliance through a reverse stock split, if necessary.

The molecular diagnostics company has been given 60 days to demonstrate that it's in compliance with TSX listing requirements.

The firm, which was previously listed on the over-the-counter market, anticipates $8.5 million in net proceeds from the offering.

The Australian firm regained compliance on a rule for a minimum $1 bid on its shares, while its deadline to meet a rule for a minimum $2.5 million in shareholders' equity was extended. 

NEW YORK (GenomeWeb News) – NeoGenomics has been approved to list its shares on the Nasdaq Capital Market, the Ft. Myers, Fla.-based firm said today.

NEW YORK (GenomeWeb News) – Trovagene announced late on Tuesday the pricing of a public offering of 1.15 million units and said that its shares will begin trading on the Nasdaq Capital Market today under ticker symbol "TROV".

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Rosetta Genomics disclosed it has been warned by the Nasdaq that it is not in compliance with a listing requirement.

Pages

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.